NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of Akorn, Inc. (NASDAQ:AKRX) resulting from allegations that Akorn may have issued materially misleading business information to the investing public.
On February 26, 2018, Fresenius SE & Co. KGaA, which agreed to buy Akorn last April, announced it is “conducting an independent investigation, using external experts, into alleged breaches of FDA [Food and Drug Administration] data integrity requirements relating to product development at Akorn, Inc.” Fresenius also stated the “consummation of the transaction may be affected if the closing conditions under the merger agreement are not met.” On this news, Akorn securities have fallen sharply during intraday trading on February 27, 2018.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Akorn investors. If you purchased Akorn, please visit the firm’s website at http://www.rosenlegal.com/cases-1301.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.